Agency Information Collection Activities: Proposed Collection; Comments Requested, 3542-3543 [E6-681]
Download as PDF
erjones on PROD1PC61 with NOTICES
3542
Federal Register / Vol. 71, No. 14 / Monday, January 23, 2006 / Notices
The Secretary will maintain a public
service list containing the names and
addresses of all persons, or their
representatives, who are parties to the
reviews.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
section 207.7(a) of the Commission’s
rules, the Secretary will make BPI
gathered in these reviews available to
authorized applicants under the APO
issued in the reviews, provided that the
application is made by 45 days after
publication of this notice. Authorized
applicants must represent interested
parties, as defined by 19 U.S.C. 1677(9),
who are parties to the reviews. A party
granted access to BPI following
publication of the Commission’s notice
of institution of the reviews need not
reapply for such access. A separate
service list will be maintained by the
Secretary for those parties authorized to
receive BPI under the APO.
Staff report.—The prehearing staff
report in the reviews will be placed in
the nonpublic record on April 28, 2006,
and a public version will be issued
thereafter, pursuant to section 207.64 of
the Commission’s rules.
Hearing.—The Commission will hold
a hearing in connection with the
reviews beginning at 9:30 a.m. on May
18, 2006, at the U.S. International Trade
Commission Building. Requests to
appear at the hearing should be filed in
writing with the Secretary to the
Commission on or before May 12, 2006.
A nonparty who has testimony that may
aid the Commission’s deliberations may
request permission to present a short
statement at the hearing. All parties and
nonparties desiring to appear at the
hearing and make oral presentations
should attend a prehearing conference
to be held at 9:30 a.m. on May 15, 2006,
at the U.S. International Trade
Commission Building. Oral testimony
and written materials to be submitted at
the public hearing are governed by
sections 201.6(b)(2), 201.13(f), 207.24,
and 207.66 of the Commission’s rules.
Parties must submit any request to
present a portion of their hearing
testimony in camera no later than 7
business days prior to the date of the
hearing.
Written submissions.—Each party to
the reviews may submit a prehearing
brief to the Commission. Prehearing
briefs must conform with the provisions
of section 207.65 of the Commission’s
rules; the deadline for filing is May 9,
2006. Parties may also file written
testimony in connection with their
presentation at the hearing, as provided
in section 207.24 of the Commission’s
VerDate Aug<31>2005
13:01 Jan 20, 2006
Jkt 208001
rules, and posthearing briefs, which
must conform with the provisions of
section 207.67 of the Commission’s
rules. The deadline for filing
posthearing briefs is May 26, 2006;
witness testimony must be filed no later
than three days before the hearing. In
addition, any person who has not
entered an appearance as a party to the
reviews may submit a written statement
of information pertinent to the subject of
the reviews on or before May 26, 2006.
On June 20, 2006, the Commission will
make available to parties all information
on which they have not had an
opportunity to comment. Parties may
submit final comments on this
information on or before June 22, 2006,
but such final comments must not
contain new factual information and
must otherwise comply with section
207.68 of the Commission’s rules. All
written submissions must conform with
the provisions of section 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s rules do not
authorize filing of submissions with the
Secretary by facsimile or electronic
means, except to the extent permitted by
section 201.8 of the Commission’s rules,
as amended, 67 FR 68036 (November 8,
2002). Even where electronic filing of a
document is permitted, certain
documents must also be filed in paper
form, as specified in II(C) of the
Commission’s Handbook on Electronic
Filing Procedures, 67 FR 68168, 68173
(November 8, 2002).
Additional written submissions to the
Commission, including requests
pursuant to section 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with sections 201.16(c)
and 207.3 of the Commission’s rules,
each document filed by a party to the
reviews must be served on all other
parties to the reviews (as identified by
either the public or BPI service list), and
a certificate of service must be timely
filed. The Secretary will not accept a
document for filing without a certificate
of service.
Authority: These reviews are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.62 of the
Commission’s rules.
By order of the Commission.
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Issued: January 17, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–723 Filed 1–20–06; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Agency Information Collection
Activities: Proposed Collection;
Comments Requested
30-Day Notice of Information
Collection Under Review: Prescription
Monitoring Program Questionnaire.
ACTION:
The Department of Justice (DOJ), Drug
Enforcement Administration (DEA) has
submitted the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. This
proposed information collection was
previously published in the Federal
Register (Volume 70, Number 190, page
57622) on October 3, 2005, allowing for
a 60-day comment period.
The purpose of this notice is to allow
for an additional 30 days for public
comment until February 22, 2006. This
process is conducted in accordance with
5 CFR 1320.10.
Written comments and/or suggestions
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503.
Additionally, comments may be
submitted to OMB via facsimile to (202)
395–5806. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
E:\FR\FM\23JAN1.SGM
23JAN1
3543
Federal Register / Vol. 71, No. 14 / Monday, January 23, 2006 / Notices
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Prescription Monitoring Program
Questionnaire.
(3) Agency form number, if any, and
the applicable component of the
Department sponsoring the collection:
Form number: None. Office of Diversion
Control, Drug Enforcement
Administration, Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: State. Other: None.
This questionnaire permits the Drug
Enforcement Administration to compile
and evaluate information regarding the
design, implementation and operation
of state prescription monitoring
programs. Such information allows DEA
to assist states in the development of
new programs designed to enhance the
ability of both DEA and state authorities
to prevent, detect, and investigate the
diversion and abuse of controlled
substances.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 26 persons
complete the Prescription Monitoring
Program Questionnaire on paper and 25
persons complete the form
electronically, at 5 hours per form, for
an annual burden of 255 hours.
(6) An estimate of the total public
burden (in hours) associated with the
collection: It is estimated that there are
255 annual burden hours associated
with this collection.
If additional information is required
contact: Brenda E. Dyer, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Patrick Henry Building,
Suite 1600, 601 D Street, NW.,
Washington, DC 20530.
Dated: January 17, 2006.
Brenda E. Dyer,
Department Clearance Officer, Department of
Justice.
[FR Doc. E6–681 Filed 1–20–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 17, 2005,
Cerilliant Corporation, 811 Paloma
Drive, Suite A, Round Rock, Texas
78664, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
I and II:
erjones on PROD1PC61 with NOTICES
Drug
Schedule
Cathinone (1235) .........................................................................................................................................................................................
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ..............................................................................................................................................................
Aminorex (1585) ..........................................................................................................................................................................................
4-Methylaminorex (cis isomer) (1590) .........................................................................................................................................................
Gamma Hydroxybutyric acid (2010) ............................................................................................................................................................
Methaqualone (2565) ..................................................................................................................................................................................
Alpha-Ethyltryptamine (7249) ......................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
Marihuana (7360) ........................................................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) .........................................................................................................................................................................................
3,4,5-Trimethoxyamphetamine (7390) ........................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ..............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ..........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ..............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
5-Methoxy-3,4-methylenedioxyamphetamine (7401) ..................................................................................................................................
N-Hydroxy-3,4-methylendioxyamphetamine (7402) ....................................................................................................................................
3,4-Methylendioxy-N-ethylamphetamine (7404) ..........................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
Bufotenine (7433) ........................................................................................................................................................................................
Diethyltryptamine (7434) .............................................................................................................................................................................
Dimethyltryptamine (7435) ..........................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
Psilocyn (7438) ............................................................................................................................................................................................
Acetyldihydrocodeine (9051) .......................................................................................................................................................................
Benzylmorphine (9052) ...............................................................................................................................................................................
Codeine-N-oxide (9053) ..............................................................................................................................................................................
Dihydromorphine (9145) ..............................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Hydromorphinol (9301) ................................................................................................................................................................................
Methyldihydromorphine (9304) ....................................................................................................................................................................
Morphine-N-oxide (9307) .............................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Pholcodine (9314) .......................................................................................................................................................................................
VerDate Aug<31>2005
13:01 Jan 20, 2006
Jkt 208001
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
E:\FR\FM\23JAN1.SGM
23JAN1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Agencies
[Federal Register Volume 71, Number 14 (Monday, January 23, 2006)]
[Notices]
[Pages 3542-3543]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-681]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Agency Information Collection Activities: Proposed Collection;
Comments Requested
ACTION: 30-Day Notice of Information Collection Under Review:
Prescription Monitoring Program Questionnaire.
-----------------------------------------------------------------------
The Department of Justice (DOJ), Drug Enforcement Administration
(DEA) has submitted the following information collection request to the
Office of Management and Budget (OMB) for review and approval in
accordance with the Paperwork Reduction Act of 1995. The proposed
information collection is published to obtain comments from the public
and affected agencies. This proposed information collection was
previously published in the Federal Register (Volume 70, Number 190,
page 57622) on October 3, 2005, allowing for a 60-day comment period.
The purpose of this notice is to allow for an additional 30 days
for public comment until February 22, 2006. This process is conducted
in accordance with 5 CFR 1320.10.
Written comments and/or suggestions regarding the items contained
in this notice, especially the estimated public burden and associated
response time, should be directed to the Office of Management and
Budget, Office of Information and Regulatory Affairs, Attention
Department of Justice Desk Officer, Washington, DC 20503. Additionally,
comments may be submitted to OMB via facsimile to (202) 395-5806.
Written comments and suggestions from the public and affected agencies
concerning the proposed collection of information are encouraged. Your
comments should address one or more of the following four points:
--Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility;
--Evaluate the accuracy of the agencies estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used;
[[Page 3543]]
--Enhance the quality, utility, and clarity of the information to be
collected; and
--Minimize the burden of the collection of information on those who are
to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses.
Overview of This Information Collection
(1) Type of Information Collection: Extension of a currently
approved collection.
(2) Title of the Form/Collection: Prescription Monitoring Program
Questionnaire.
(3) Agency form number, if any, and the applicable component of the
Department sponsoring the collection: Form number: None. Office of
Diversion Control, Drug Enforcement Administration, Department of
Justice.
(4) Affected public who will be asked or required to respond, as
well as a brief abstract: Primary: State. Other: None. This
questionnaire permits the Drug Enforcement Administration to compile
and evaluate information regarding the design, implementation and
operation of state prescription monitoring programs. Such information
allows DEA to assist states in the development of new programs designed
to enhance the ability of both DEA and state authorities to prevent,
detect, and investigate the diversion and abuse of controlled
substances.
(5) An estimate of the total number of respondents and the amount
of time estimated for an average respondent to respond: It is estimated
that 26 persons complete the Prescription Monitoring Program
Questionnaire on paper and 25 persons complete the form electronically,
at 5 hours per form, for an annual burden of 255 hours.
(6) An estimate of the total public burden (in hours) associated
with the collection: It is estimated that there are 255 annual burden
hours associated with this collection.
If additional information is required contact: Brenda E. Dyer,
Department Clearance Officer, United States Department of Justice,
Justice Management Division, Policy and Planning Staff, Patrick Henry
Building, Suite 1600, 601 D Street, NW., Washington, DC 20530.
Dated: January 17, 2006.
Brenda E. Dyer,
Department Clearance Officer, Department of Justice.
[FR Doc. E6-681 Filed 1-20-06; 8:45 am]
BILLING CODE 4410-09-P